Abstract Background: Pregnancy of women with heart disease is still a challenging condition because it is associated with elevated maternal and fetal morbidity and mortality. In the clinical setting, an accurate individual risk assessment is of fundamental importance. Patients and methods: The current study was carried out in the Department of Cardiology, & the Department of Obstetrics, El-Minia University during the period from January 2009 to December 2009. We surveyed 150 pregnant ladies with structural heart disease as a part of the Euro Heart Survey on pregnancy & heart disease; they were followed up till 6 weeks postpartum. The follow-up of 121 cases during pregnancy and postpartum period was completed; there were 23 cases still pregnant while the follow-up of 6 cases was missed. So we included the 121 cases in our statistical analysis regarding maternal and fetal events during pregnancy, delivery & postpartum. Inclusion criteria: All patients with structural heart disease, valvular heart disease, congenital heart disease, ischemic heart disease, cardiomyopathy, pulmonary hypertension presenting with pregnancy, independent of age, any concomitant diseases and type of heart disease had been enrolled. Structural heart disease was diagnosed through full history taking, clinical examination and investigations such as ECG & echocardiography. Exclusion criteria: Non-structural heart disease even arrhythmias occurring in the context of a normal heart. A follow-up of all patients had been performed for at least 6 weeks after delivery using telephone contact or in our outpatient clinic (for heart disease with pregnancy) in the El-Minia University Hospital. Results: 78% cases were with valvular heart disease, 7.3% with congenital heart disease, 10.7% with cardiomyopathy, 2% with ischemic heart disease while 0.6% cases with Lutembacher syndrome and 1.3% cases with pulmonary hypertension. Maternal cardiovascular complications during pregnancy were heart failure 6.6%, thrombotic complications: 0.8%, arrhythmia 1.6%, and hemorrhagic complications 2.5%. Maternal mortality was 3.3%, 30.4% of the high-risk group 
Introduction
Approximately 2% of pregnancies involve maternal cardiovascular disease and this poses an increased risk to both mother and fetus. Most women with cardiovascular disease can experience pregnancy with proper care, but a careful prepregnancy evaluation is mandatory. Sometimes, cardiac disease may manifest for the first time in pregnancy, because the hemodynamic changes may compromise a limited cardiac reserve. 1 Many factors ultimately determine the counseling and guidance during pregnancy and the mode of delivery of individual patients with heart disease in a given community. A multidisciplinary team approach with cardiologists, obstetricians and anesthetists during pregnancy, delivery and the postpartum period is recommended. 2 Collectively, these women have a spectrum of structural heart disease including congenital heart disease, rheumatic heart disease, pulmonary hypertension, cardiomyopathy and coronary artery disease. The heterogeneous nature of this group means that the information we use to develop our management protocols is incomplete and fragmented. To be able to practice to the standard demanded by an ''Evidence Based Medicine'' approach it is imperative that we establish a prospective registry.
The aim of the study
The aim of this work is to demonstrate the variation of structural heart disease in pregnant ladies in our locality, detect maternal & fetal complications and to predict the risk factors for poor maternal, fetal & neonatal outcomes.
Methods
The current study was carried out in the Department of Cardiology, and the Department of Obstetrics, El-Minia University during the period from January 2009 to December 2009. We surveyed 150 pregnant ladies with structural heart disease as part of the Euro Heart Survey on pregnancy, heart disease; they were followed up till 6 weeks postpartum. The followup of 121 cases during pregnancy and postpartum period was completed; there were 23 cases still pregnant while the follow-up of 6 cases was missed. We included the 121 cases in our study regarding maternal and fetal events during pregnancy, delivery, and postpartum. Inclusion criteria: All patients with structural heart disease, valvular heart disease, congenital heart disease, ischemic heart disease, cardiomyopathy, and pulmonary hypertension, presenting with pregnancy, independent of age, any concomitant diseases and type of heart disease have been enrolled. Structural heart disease was diagnosed through full history taking, clinical examination and investigations such as ECG & echocardiography.
Exclusion criteria: Non-structural heart disease even arrhythmias occurring in the context of a normal heart. A follow-up of all patients had been performed for at least 6 weeks after delivery using telephone contact or in our outpatient clinic (for heart disease with pregnancy) in the El-Minia University Hospital. Electronic Case Report Form (CRF): [I] Patient characteristics: age, gestational age, parity status, and major noncardiac diseases; risk factors (diabetes mellitus, hypertension and smoking status]); New York Heart Association (NYHA) functional class; past history relevant to the structural heart disease and obstetric history.
[II] Present pregnancy: documentation of cardiac events during pregnancy (heart failure, thrombo-embolic complications, hemorrhagic complications, endocarditis, arrhythmias & acute coronary syndrome) and documentation of obstetric events during pregnancy [small for gestational age, IUFD (20 weeks gestation and before birth), pregnancy-induced hypertension, pre-eclampsia and eclampsia].
Pregnancy-induced hypertension was defined as an increase of 30 mmHg in systolic blood pressure and 15 mmHg in diastolic blood pressure compared with baseline values. 3 Preeclampsia was defined as gestational hypertension (systolic blood pressure P 140 mmHg and/or diastolic blood pressure P 90 mmHg on at least two occasions four hours apart after 20 weeks' gestation, but before the onset of labor, or postpartum systolic blood pressure P 140 mmHg and/or diastolic blood pressure P 90 mmHg on at least two occasions 4 h apart) with proteinuria (24 h urinary protein P 300 mg, or spot urine protein to creatinine ratio P 30 mg/mmol creatinine, or urine dipstick protein P 2+) or any multisystem complication of pre-eclampsia. 4 Use of cardiac medications and anticoagulants. Mode and place of delivery. Complications during delivery.
The following data regarding the neonate were documented: Gender, number, pregnancy duration and APGAR score: The test was done at 1 and 5 min after birth, and may be repeated later if the score is and remains low. 5 Neonatal complications: Premature birth (<37 weeks gestation), smallfor-gestational-age birth weight (<10th percentile for gestational age), congenital heart disease in babies of mothers with congenital heart disease by clinical examination and echocardiography if indicated, respiratory distress syndrome, or neonatal death. 3, 4 Maternal and fetal outcomes after pregnancy: The following details were documented: Maternal & neonatal morbidity & mortality till the end of follow-up period. All TIMI definitions take into account blood transfusions, so that hemoglobin and hematocrit values are adjusted by 1 g/dl and 3%, respectively, for each unit of blood transfused. Therefore, . 6 Pulse rate of <60 is considered asystole in a neonate. The test was done at 1 and 5 min after birth, and may be repeated later if the score is and remains low. 5 To investigate the relationship between the severity of maternal heart disease and maternal and fetal/neonatal, patients were divided into a high and low-risk groups according to ACC/ AHA 2006 guidelines for the management of patients with valvular heart disease. 7 
Statistical analyses
Discrete values were presented as counts and percentages. Values were expressed as mean ± SD. Significance was 
Results
The results of the study are arranged into these items:
-Demographics of the study population.
-Pregnancy course.
-Delivery and outcome.
-Predictors of poor maternal outcome.
-Predictors of poor fetal & neonatal outcomes.
The baseline characteristics of the study population are shown in Table 1 .
Anticoagulation was indicated in 16 cases: 10 cases with mechanical valve prostheses, 3 cases with AF, a case with severe 1ry pulmonary hypertension, a case had RHD associated with antiphospholipid antibody syndrome, history of CV, stroke & recurrent abortions. Patients are classified as regards anticoagulation during 1st trimester of pregnancy into two groups:
Group I: 8 patients with regimen I anticoagulation (unfractionated heparin 1st trimester and 2 weeks prepartum).
Group II: 8 patients with regimen II anticoagulation (warfarine throughout the pregnancy with 2 weeks prepartum covered by heparin).
The cardiac medications & investigations of the study population are shown in Table 2 .
The classification of the study population according to NYHA class are shown in Fig. 1 Variation of structural heart disease in pregnant patients in El-Minia locality: In total, 117 (78%) cases had valvular heart disease, 11 (7.3%) had congenital heart disease, 16 (10.7%) had cardiomyopathy, 3 (2%) had ischemic heart disease, while 1 (0.6%) case had Lutembacher syndrome and 2 (1.3%) cases were with pulmonary hypertension (Table 3) .
Pregnancy course: (A) Maternal cardiovascular complications: (1) Heart failure 6.6%: During pregnancy 6 women had left sided heart failure (3 cases had peripartum cardiomyopathy, 2 cases had RHD with moderate to severe MS, 1 case had severe AS, the case who had severe primary pulmonary hypertension (PASP = 110 mmHg), the last case had dilated cardiomyopathy). (C) Maternal complications during delivery (Table 5) :
-Acute heart failure & cardiogenic shock (16 cases).
-Acute myocardial infarction (1 case).
(D) Maternal mortality 3.3% (4 patients). (E) Neonatal outcome (Table 6 ):
Two mothers with congenital heart disease had neonates with ASD. Three cases had neonatal respiratory distress & neonatal ICU admission with 1 (0.8%) case had neonatal mortality.
Heart failure complications were found in 19.7% of pregnant women with heart disease during pregnancy and peripartum period. We found the following: 54.2% were with peripartum cardiomyopathy, 29% with RHD, 4.2% with idiopathic dilated cardiomyopathy, 4.2% with Eisenmenger's syndrome, and 8.4% with severe pulmonary hypertension.
Predictors of poor maternal outcome (Table 7) : (A) Predictors of maternal mortality: Mean maternal age was = 26 ± 5.2: (Table 9) .
(D) Predictors of hemorrhagic complications: Anticoagulation therapy (66.7%, p = 0.004) ( Table 10) .
Predictors of poor fetal & neonatal outcomes (Table 11) 30.4% of the high-risk group suffered from maternal complications in comparison to only 9.5% of the women at lowrisk. Accordingly, the high-risk group (30.4%) had a 3.1-fold greater severe maternal event rate; maternal mortality was 8.2% of the women in high-risk group versus 0% in the lowrisk group. Also fetal complications occurred in 14.3% of the high-risk group versus 0% in low-risk group. APGAR score & birth weight were much lower in the high-risk group (p value 0.001). The majority of cases (83.7%) in the high-risk group conceived without preconceptional counseling. As regards significance of preconceptional counseling and preconceptional NYHA class, we found the following: There were 4 cases with NYHA III preconceptionally. Therapeutic abortion was indicated in 2 cases with NYHA class III presented to us early in 1st trimester. In another case complicated by acute pulmonary edema, mechanical ventilation was indicated. The last case was complicated with CHF, cardiogenic shock & IUFD (Tables 12 and 13 ).
Discussion
Structural heart disease with pregnancy in El-Minia locality in this study was 1.66 per 100 deliveries in the period from 1 January 2009 to 12 December 2009. In western countries, maternal heart disease complicates 1-3% of pregnancies. 1, 8 This study in El-Minia locality, demonstrated that RHD was responsible for the majority (66.7%) of the cases of heart disease in pregnancy, while congenital heart diseases represented 7.3% & cardiomyopathies represented 10.7%. In Sa˜o Paulo, Brazil, Avila et al. documented in their study that the incidence of rheumatic heart disease was 55.7%, while congenital heart disease represented 19.1% and cardiomyopathies were 4.3%. 9 In European countries, congenital heart diseases were responsible for the majority of the cases of heart disease with pregnancy in the Euro-Heart survey, congenital heart disease (65%), valvular heart disease (25%), cardiomyopathy (1%) and IHD (5%). 10, 16 Regimen I anticoagulation was associated with (25%) fetal loss and surprisingly 0% maternal thrombotic complications, while regimen II anticoagulation was associated with 50% fetal loss and 12.5% maternal thrombotic complica- Table 7 The relation between patient characteristics and maternal mortality. tions. This strange result may be due to negligence & lack of regular follow-up of INR in regimen II while all patients in group I were admitted to hospital with proper heparin dose adjustment guided with aPTT. Gelson et al. 11 found that heparin for 6-12 weeks, followed by warfarine to 38 weeks, followed by LSCS was associated with 9% maternal thromboembolism & 30% fetal loss with 0% fetal abnormality. While warfarine until 38 weeks, followed by elective LSCS was associated with 4% maternal thromboembolism & 30% fetal loss with 6% fetal abnormality. Our results were in disagreement with Stangl et al., 10 who documented a 12.9% incidence of maternal cardiovascular events during pregnancy in women with congenital and acquired heart disease. However Koregol et al. 12 found that the incidence of cardiac complications was 18%. In our study left sided heart failure occurred in 4.9% during pregnancy while it occurred in 13.2% during delivery, cardiogenic shock occurred in 0.8% during pregnancy, while it occurred in 1.6% during delivery & early postpartum period. However in a study done by Koregol et al. 12 in Karnataka state, India, the incidence of pulmonary edema during pregnancy was 10.9%. In disagreement with our results in a study done by Stangl et al., 10 the incidence of heart failure was 6.5%. In our study there was one case 0.8% who had life threatening thrombosis of the mitral valve prosthesis. In agreement with our results Siu et al. 13 documented that embolic strokes occurred in 0.7% of pregnancies. However Stangl et al. 10 found a higher incidence of severe thrombotic complications, 2.2%. In our study there was 0.8% newly developed atrial fibrillation and 0.8% paroxysmal supraventricular tachycardia. However Koregol et al. 12 mentioned that the incidence of atrial fibrillation was 2.7%. Infective endocarditis in our study was 0%. In agreement with our results Stangl et al. 10 found the same incidence. While Avila et al. 9 found that the incidence was 0.5%. In disagreement with our results Koregol et al. 12 found that bacterial endocarditis occurred in 4.5% of cases. Maternal mortality, in our study was 3.3% maternal deaths 2.5% due to cardiac causes while 0.8% due to other causes. This was comparable with Koregol et al., 12 who reported 3.6% maternal deaths. In disagreement with our results Stangl et al. 10 reported that maternal mortality was 1.1%, while the Eurobservational Research Programme 2010 found HF: 11%, AF: 2%, ventricular arrhythmia: 1%, hemorrhagic complication: 1%, ACS: 0.5%, thrombo-embolic events: 0.3%, and endocarditis: 0.2%. 16 Mode of delivery: In our study 54.5% of cases were delivered vaginally, while 45.5% were delivered by CS. 26.5% due to cardiac indication and 19% were due to obstetric cause. However Koregol 12 reported that the majority of cases delivered vaginally 72.8% and cesarean section 27.2% was done for obstetric indications only. Avila et al. 9 reported that vaginal delivery occurred in 65% patients and cesarean section in 35% women, while Eurobservational Research Programme 2010 found vaginal delivery represented 54%, and cesarian 46%. 16 In our study fetal and neonatal outcomes were 4.1% small for gestational age, 5% IUFD, 1.7% congenital heart diseases in neonates, 0.8% neonatal ICU admission with respiratory and 1.7% neonatal mortality with respiratory distress. Birth Table 8 The relation between patients characteristics and heart failure during pregnancy. Table 9 The relation between patient characteristics and thromboembolic complications. Anticoagulant regimen I (unfractionated heparin 1st trimester and 2 weeks prepartum). Anticoagulant regimen II (warfarine all over the pregnancy with 2 weeks prepartum covered by heparin). Anticoagulant regimen I (unfractionated heparin 1st trimester and 2 weeks prepartum). Anticoagulant regimen II (warfarine all over the pregnancy with 2 weeks prepartum covered by heparin. Anticoagulant regimen I (unfractionated heparin 1st trimester and 2 weeks prepartum). Anticoagulant regimen II (warfarine all over the pregnancy with 2 weeks prepartum covered by heparin). 12 reported that the incidence of IUFD/still birth was 6.8%, small for gestational age was 46.3%, congenital heart disease of baby was 0%. Mean birth weight was 2.54 kg, and 30.1% babies required neonatal intensive care unit admission. Neonatal death was 2.9%, 12 while Eurobservational Research Programme 2010 found neonatal mortality as 0.46% and mean birth weight 3 kg. 16 In our study 44.6% of cases were symptomatic (41.3% NYHA functional class II & 3.3% NYHA class III). Both maternal morbidity and mortality are high in pregnant women with poor functional class. 75% of maternal mortality was NYHA class II & III (p = 0.02). In agreement with our results Sawhney et al. 14 showed that eight of 10 maternal deaths (80%) occurred in patients with NYHA class III and IV. Also in agreement with our results Koregol et al. 12 showed that patients with NYHA class III and IV had the worst maternal and perinatal outcomes. Bonow et al. 7 classified valvular heart lesions according to maternal, fetal, and neonatal risks into high-risk & low-risk groups. In our study, a total of 30.4% of the high-risk group suffered from maternal complications in comparison to only 9.5% of the women at low-risk; maternal mortality was 8.2% of the women in high-risk group versus 0% in the low-risk group. Also fetal complications occurred in 14.3% of the high-risk group versus 0% in low-risk group. AP-GAR score & birth weight were much lower in the high-risk group (p value 0.001). The majority of cases (83.7%) in the high-risk group conceived without preconceptional counseling. In agreement with our results Drenthen et al. 15 reported that mechanical valve prosthesis is one of the predictors of maternal cardiac complications. In our study we reported the following predictors of poor maternal outcome. 13 reported the following predictors of cardiac complications, prior cardiac event or arrhythmia (p < 0.001), NYHA functional class > II or cyanosis (p = 0.009), left heart obstruction (p < 0.001) and systemic ventricular dysfunction (p < 0.001).
Conclusions
RHD is the commonest cardiac lesion among pregnant women. Peripartum cardiomyopathy was the 1st etiology of heart failure in our study but fortunately it had a good prognosis, so assessment of the preconceptional functional class of the women with structural heart disease is so important because it has an obvious impact on the maternal and fetal morbidity and mortality, as well as in decision of continuation or termination of the pregnancy.
Recommendations
Preconceptional counseling and planned pregnancy after risk stratification of every lady with structural heart disease in the child bearing period is very important to reduce the maternal and fetal morbidity and mortality. Further trials are needed to determine the exact etiologic mechanism of peripartum cardiomyopathy. Is it a myocarditis or cardiotropic viral infection? So endomyocardial biopsies, serum autoantibodies should be searched for, also other pro-inflammatory markers and cytokines. Pregnancy is contraindicated and termination of pregnancy is recommended in the following conditions: Severe pulmonary hypertension (PA systolic pressure > 75% of systemic systolic pressure). Especially idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome. Dilated cardiomyopathy with congestive heart failure. Cyanotic congenital heart disease. Severe symptomatic stenotic valve disease, which cannot be treated using percutaneous procedures. Severe MR and AR with LV dysfunction (LVEF < 40%).
